A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Dr Fahd Quhill
Advertisement
Articles by Dr Fahd Quhill
Advertisement
Latest Updated Articles
- Intravitreal implant could bring significant cost savings to NHS England
Published: February 26th 2018 | Updated:
Advertisement
Advertisement
